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Abstract NF-UB activator 1 (Act1), also called CIKS, is a
recently identi¢ed protein with NF-UB and AP-1 activation ac-
tivities through its association with the IUB kinase complex. We
identi¢ed and con¢rmed that Act1 interacts with tumor necrosis
factor receptor-associated factor 6 (TRAF6); notably, Act1
binds to TRAF6 only among TRAF family proteins. The ami-
no-terminal half of Act1 is required for its interaction with the
TRAF domain. Act1-mediated NF-UB activation was inhibited
by a dominant-negative mutant of TRAF6 in a dose-dependent
manner, and IL-1-induced NF-UB activation was inhibited by a
high level of Act1 expression. Our results suggest that Act1 is
involved in IL-1/Toll-mediated signaling through TRAF6.
1 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Interleukin-1 (IL-1) plays an important role in in£amma-
tory responses by activating transcription factors, such as nu-
clear factor kappa B (NF-UB), AP-1, and ATF [1^3]. The IL-
1-induced signaling pathway for NF-UB activation has been
studied extensively, and a plausible working model has been
proposed [4^6]. When IL-1 binds to its receptor (IL-1R), a
receptor complex comprising IL-1R and its coreceptor (IL-
1RAcP) is formed [7]. The cytoplasmic proteins MyD88 (pro-
tein encoded in myeloid di¡erentiation gene 88) [8] and Tollip
(Toll-interacting protein) [9] are both recruited to the receptor
complex, resulting in recruitment of IL-1 receptor-associated
kinase 1 (IRAK1) [10]. IRAK1 is activated by autophosphor-
ylation, disassociates from the complex, and interacts with
tumor necrosis factor receptor-associated factor 6 (TRAF6)
[11], a key adapter molecule in the pathway. The IRAK1^
TRAF6 complex activates the TAB1/TAK1^NIK (transform-
ing growth factor-L activated kinase 1 (binding) protein^NF-
UB-inducing kinase) pathway [5,12], leading to activation of
the IUB kinase (IKK) complex that is essential to activate NF-
UB [13]. Because the molecular mechanisms downstream of
IRAK1 in the IL-1-induced signaling pathway are shared by
those of the Toll signaling pathway, the pathway is also called
the IL-1/Toll signaling pathway [6]. Activated TAK1 is also
implicated in the activation of SAPK/JNK (c-Jun N-terminal
kinase), a member of the MAPK kinase kinase (MAPKKK)
family. It is also proposed that IL-1-induced activation of
JNK may diverge from NF-UB activation at the level of
TRAF6 [14].
NF-UB activator 1 (Act1), also called CIKS (connection to
IKK and SAPK/JNK), has previously been identi¢ed as an
NF-UB and JNK-activating protein by two independent
groups [15,16]. Act1 does not have any enzymatic domain;
instead it contains a helix-loop-helix at the amino terminus
and a coiled-coil motif at the carboxyl terminus. Direct inter-
action of Act1 with the IKK complex leads to NF-UB activa-
tion. This mechanism is supported also by the result that a
kinase-de¢cient dominant-negative mutant of NIK does not
a¡ect Act1-mediated NF-UB activation. Despite clear evidence
of the signaling pathway downstream of Act1 that leads to
activation of NF-UB, the signal that modulates Act1 activity
has not been clari¢ed. Recently, Qian et al. [17] reported that
Act1 is recruited to the CD40 receptor in epithelial cells upon
their stimulation with CD40 ligand, suggesting that Act1
plays a role in CD40-mediated signaling. However, these au-
thors also described their seemingly inconsistent result that
Act1 interacts with TRAF3, as TRAF3 seems to play a neg-
ative role in Act1-dependent CD40-mediated NF-UB activa-
tion [17].
Here we report the identi¢cation and con¢rmation of Act1
interaction with TRAF6, an adapter molecule essential for
NF-UB activation in the IL-1/Toll signaling pathway. We
also propose a working model for the signal-transduction
mechanism of Act1 that is consistent with our present data.
2. Materials and methods
2.1. Cell culture
Human embryonic kidney cell line HEK293 was cultured in mini-
mum essential medium supplemented with 10% heat-inactivated fetal
bovine serum (FBS), 200 U/ml penicillin, and 200 Wg/ml streptomycin.
CHO-K1 cells were maintained in F-12 Nutrient Mixture (Ham’s
F-12), both supplemented with 10% FBS and antibiotics. Both cells
were purchased from the RIKEN cell bank Japan.
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2.2. Mammalian two-hybrid assay
The detailed method has been published in [18]. Brie£y, the assay
samples were prepared by two-step polymerase chain reaction (PCR);
we constructed the PCR products to express fusion proteins with the
Gal4 DNA-binding or herpes virus VP16 transcriptional activation
domains. We transfected the PCR products together with 20 ng of
the reporter plasmid pG5luc (Promega, CA, USA) into 2.2U104
CHO-K1 cells by using the transfection reagent LF2000 (Invitrogen,
Groningen, The Netherlands) according to the manufacturer’s instruc-
tions. After 20 h of incubation, the luciferase reporter activity was
measured with the Steady-Glo Luciferase Assay System (Promega).
2.3. Co-immunoprecipitation analysis
The detailed method has been published in [19]. The protein-coding
sequences of Act1 and TRAF6 cDNAs were ampli¢ed by PCR and
subcloned into the expression vectors pCMV-HA and pCMV-Myc
(Clontech, CA, USA), respectively. We then transfected 1U106
HEK293 cells with 2.5 Wg of the expression vectors for HA-tagged
Act1 (HA-Act1) and Myc-tagged TRAF6 (Myc-TRAF6) by using
LF2000. After 24 h, cells were harvested and lysed by TNE bu¡er
[19]. After centrifugation at 10 000Ug for 15 min, the supernatants
were isolated and immunoprecipitated with 5 Wg anti-HA antibody
(Santa Cruz, CA, USA). The co-precipitated Myc-TRAF6 was de-
tected by Western blot analysis. The supernatants described above
were also subjected to direct Western blot analysis to con¢rm the
expression of HA-ACT1 and Myc-TRAF6.
2.4. Glutathione S-transferase pull-down assays
In vitro transcription and translation of TRAF6 was performed
with the TNT T7 Quick Master Mix kit (Promega) in the presence
of [35S]methionine, according to the manufacturer’s protocol. Gluta-
thione S-transferase (GST) or the GST-Act1 fusion protein was ex-
pressed in Escherichia coli and puri¢ed. An aliquot of GST-Act1 or
GST, bound to glutathione^Sepharose beads (Amersham, Bucking-
hamshire, UK), was incubated with 5 Wl of in vitro translated
TRAF6 in 500 Wl NETN bu¡er (100 mM NaCl, 1 mM EDTA [pH
8.0], 20 mM Tris^HCl [pH 8.0], 0.2% NP40) for 6 h. Beads were
washed ¢ve times with 1 ml NETN bu¡er, resuspended in Laemmli
sample bu¡er, and subjected to sodium dodecyl sulfate^polyacryl-
amide gel electrophoresis (SDS^PAGE) before autoradiography.
2.5. Reporter gene analysis
The expression vectors for Act1 and a dominant-negative mutant of
TRAF6 that lacks amino acid residues 1^226 (dnTRAF6) were each
transfected with 10 ng of the reporter vector pNFUB-Luc (Clontech)
into 5U104 HEK293 cells per well of a 96-well plate by using LF2000.
After 24 h, cells were treated or untreated with 10 ng/ml IL-1 (RpD
systems, MN, USA) for 6 h. The luciferase activity of the reporter
gene was measured as described previously.
3. Results
3.1. Interaction of Act1 with TRAF6
We previously reported the development of a novel assay
system for the systematic analysis of protein^protein interac-
tions, which involves rapid, PCR-mediated sample prepara-
tion and a high-throughput assay system based on the mam-
malian two-hybrid method [18]. Using our previously
developed system, we systematically assayed approximately
6000 cDNAs derived from mouse full-length enriched cDNA
libraries. We detected strong luciferase reporter activity cor-
responding to an interaction between Act1 and TRAF6 when
TRAF6 was used as a prey sample (Fig. 1A). To con¢rm the
interaction, we carried out a co-immunoprecipitation experi-
ment (Fig. 1B). We transfected the expression vectors for HA-
Act1 and Myc-TRAF6 into HEK293 cells and subjected the
cell extracts to immunoprecipitation using an anti-HA anti-
body. Western blot analysis using an anti-Myc antibody
showed that Myc-TRAF6 was speci¢cally co-immunoprecipi-
tated with HA-Act1 (top panel, Fig. 1B). We con¢rmed the
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Fig. 1. Identi¢cation and con¢rmation of the interaction between
Act1 and TRAF6. A: Identi¢cation of Act1 interaction with
TRAF6. The relative luciferase activity of the reporter gene was
measured when TRAF6 (prey) and Act1 (bait) were co-transfected
with the reporter vector pG5luc into CHO-K1 cells. Mean values
for transfections of either bait- or prey-samples were calculated as
baselines. The nucleotide sequence for mouse Act1 cDNA has been
deposited in the DDBJ/EMBL/GenBank database (accession no.
AK031556). B: Co-immunoprecipitation of Act1 and TRAF6. The
expression vectors encoding HA-Act1 and Myc-TRAF6 were trans-
fected into HEK293 cells as indicated at the top of the panel. Cell
extracts were immunoprecipitated by using an anti-HA antibody.
The co-precipitated Myc-TRAF6 was detected by Western blot
analysis using an anti-Myc antibody (top row). The extracts were
also subjected to Western blot analysis to con¢rm the expression of
HA-Act1 (middle row) and Myc-TRAF6 (bottom row). The anti-
bodies used for immunoprecipitation (IP) and immunoblotting (IB)
are indicated to the left of the panel. C: In vitro binding of Act1 to
TRAF6. The GST^Act1 fusion protein, immobilized on gluta-
thione^Sepharose beads, was incubated with in vitro translated
[35S]-labeled TRAF6. After the beads were washed, bound TRAF6
was analyzed by SDS^PAGE and autoradiography. We did not de-
tect co-precipitated TRAF6 in incubations of glutathione^Sepharose
beads only (Beads) or GST immobilized on beads (GST).
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result by using in vitro GST pull-down assays and showed
that [35S]-labeled TRAF6 is speci¢cally co-precipitated with
GST-Act1, indicating that Act1 directly interacts with
TRAF6 (Fig. 1C). A correlation of expression pro¢les be-
tween Act1 and TRAF6 is essential for the interaction to be
biologically signi¢cant, and Northern blot analysis from sev-
eral groups indicates that both Act1 and TRAF6 are ubiqui-
tously expressed in almost all adult tissues [11,16].
3.2. Act1 speci¢cally interacts with TRAF6 through the TRAF
domain
Because TRAF6 is an adapter protein with several well-
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Fig. 2. Mapping of Act1^TRAF6 interaction domains. The interaction was examined by using the mammalian two-hybrid assay. The relative
luciferase activity of the reporter gene was measured. A: Schematic representation of TRAF6, its deletion mutants and the interactions with
wild-type Act1. B: Schematic representation of Act1, its deletion mutants, and the interaction with wild-type TRAF6. C: Interaction speci¢city
of Act1 with TRAF family proteins.
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known motifs, including the RING domain, a Zn ¢nger motif,
and the TRAF domain (Fig. 2A), we evaluated which motif is
responsible for interaction with Act1. We assessed the inter-
action of Act1 with wild-type TRAF6 or its deletion mutants
by using the mammalian two-hybrid method (Fig. 2A). Our
results showed that the minimal Act1-binding region includes
the carboxyl-terminal half of TRAF6, which is known as the
TRAF domain. We performed similar experiments to map the
region of Act1 responsible for interaction with TRAF6 (Fig.
2B). The carboxyl-terminal deletion mutants, Act1(1^355) and
Act1(1^256), could interact with TRAF6, whereas the amino-
terminal deletion mutants, Act1(236^555) and Act1(301^555),
could not. This result indicates that Act1 associates with
TRAF6 through its amino-terminal half. Recently, the crystal
structure of TRAF6 complexed with TRAF6-binding peptides
from CD40 and RANK revealed that the TRAF6-binding
motif has a consensus motif, PXEXXZ (Z, aromatic/acidic
residue) [20]. Our results are consistent with this report be-
cause this consensus motif is present in the amino-terminal
region of Act1 (PEEESE at amino acid residues 28^33 in
Fig. 2B).
The TRAF family proteins, TRAFs 1^6, are characterized
by the conserved TRAF domains in their carboxyl-terminal
regions [21,22]. We examined the speci¢city of Act1’s interac-
tion with TRAF family proteins. We detected prominent lu-
ciferase activity only corresponding to the interaction between
Act1 and TRAF6, although marginal luciferase activities oc-
curred with the interactions between Act1 and TRAFs 1^5
(Fig. 2C).
3.3. Reporter gene analysis using the expression vector for Act1
Overexpression of Act1 activates NF-UB, and this activa-
tion is mediated by association of the amino-terminal half of
Act1 with IKKQ [15,16]. To evaluate whether the interaction
between Act1 and TRAF6 leads to NF-UB activation, we
transiently co-expressed HA-Act1 and Myc-dnTRAF6(227^
530), a dominant-negative mutant of TRAF6 [11], in
HEK293 cells. The overexpression of dnTRAF6(227^530) in-
hibited Act1-mediated NF-UB activation in a dose-dependent
manner (Fig. 3A). Because dnTRAF6 itself cannot activate
NF-UB but has the TRAF domain necessary to interact
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Fig. 3. The in£uence of dnTRAF6 or IL-1 on the activation of NF-
UB by Act1. HEK293 cells in 96-well plates were transiently trans-
fected with the various expression vectors described and the reporter
vector pNFUB-Luc, followed by measurement of the reporter lucif-
erase activity. A: We co-transfected the expression vectors for Act1
(10 ng/well) and dnTRAF6. B: Cells transfected with the expression
vector for Act1 were treated (solid bars) or untreated (open bars)
with 10 ng/ml IL-1 for 6 h.
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Fig. 4. A working model for the Act1 signaling pathway. The IL-1
signaling pathway, shown by thin arrows, has been well character-
ized and involves MyD88, IRAK1, TRAF6, TAK1, TAB1, NIK,
and IKKs [6,29]. In addition, two independent groups have reported
that interaction of Act1 with IKKQ directly activates the IKK com-
plex [15,16]. We propose in the model (thick arrows) that TRAF6
functions as an anchor for Act1, retaining it in unstimulated cells,
and that activated IRAK1 associates with TRAF6, resulting in the
release of Act1. Thus, Act1 directly binds to and activates IKKs.
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with Act1, our result suggests that the overexpressed
dnTRAF6 sequesters Act1 so that Act1 cannot associate
with IKKQ to activate NF-UB.
TRAF6 transduces IL-1-induced signals to downstream
molecules such as TAB1 and TAK1, resulting in NF-UB acti-
vation [12]. To explore the relevance of the Act1^TRAF6
interaction in IL-1-induced NF-UB activation, we transfected
the expression vector for HA-Act1 into HEK293 cells and
treated them with IL-1 (Fig. 3B). We observed that Act1-
induced NF-UB activation became maximal when the vector
concentration was v 5 ng/well, and IL-1 treatment had an
additive e¡ect for NF-UB activation at concentrations 9 5
ng/well. Interestingly, the additive e¡ect disappeared when
we transfected more than 10 ng/well of Act1 expression vector
into the cells (Fig. 3B). Our results suggest that a high level of
Act1 expression interferes with IL-1-induced NF-UB activa-
tion, most likely by interaction with TRAF6.
4. Discussion
Here we describe the identi¢cation and con¢rmation of the
speci¢c interaction of Act1 with TRAF6. Our results are in-
consistent with a recent report by Qian et al., in which Act1
co-immunoprecipitated TRAF3 strongly and TRAFs 1 and 5
weakly but not TRAFs 2, 4, and 6 [17]. One of the possible
explanations for the inconsistency is that those authors used
human Act1 cDNA corresponding to a minor transcript that
is alternatively spliced, whereas we used mouse Act1 cDNA
corresponding to the human Act1 major transcript [23]. The
Act1 minor transcript possesses an extra exon encoding an
additional nine amino acids in the amino terminus of the
protein, which may a¡ect TRAF-binding speci¢city of Act1.
Further, the marginal reporter activities we observed associ-
ated with the interactions between Act1 and TRAFs 1^5 (Fig.
2C) may re£ect the interactions that Qian et al. detected in
immunoprecipitation experiments.
The interaction between Act1 and TRAF6 seems to need
neither post-translational modi¢cation nor any signaling trig-
gers, because we detected the interaction by using in vitro
translated proteins (Fig. 1C). Therefore, it is conceivable
that Act1 could associate with TRAF6 in unstimulated cells,
and this situation might explain why Act1 has not previously
been identi¢ed as a co-purifying component of the IKK com-
plex despite the strong Act1^IKKQ interaction detected by
two independent groups [15,16]. Together with our ¢nding
that overexpression of dnTRAF6 inhibited Act1-induced acti-
vation of NF-UB (Fig. 3A), these results suggest that Act1
cannot interact with and activate IKKQ unless Act1 dissoci-
ates from TRAF6. The interaction with IKKQ occurs through
the amino-terminal half of Act1 [15], and TRAF6 interacts
with Act1 in the same region. We further showed that IL-1
treatment lacked an additive e¡ect on Act1-mediated NF-UB
activation when the expression vector for Act1 was trans-
fected at high levels (Fig. 4B). In addition, the TRAF domain
of TRAF6 mediates the interaction with Act1 (Fig. 2A); acti-
vated IRAK1 binds to TRAF6 in the same region [11]. We
also con¢rmed that TRAF6 interacts with IRAK1 through
the TRAF domain (data not shown). These results suggest
that excess Act1 sequesters TRAF6 so that activated
IRAK1 cannot interact with TRAF6 to make the IRAK1^
TRAF6 complex required for the transduction of the NF-UB
activation signaling to the TAB1/TAK1^NIK pathway.
According to our experimental results, we propose a work-
ing model that accounts for the upstream signaling pathways
of Act1, in which Act1 functions in cooperation with TRAF6
to cause NF-UB activation in the IL-1/Toll signaling pathway
(Fig. 4). We hypothesize that Act1 associates with TRAF6 in
unstimulated cells. Ligand-induced activation of the IL-1R
complex (and the Toll-like receptor complex) leads to the
release of activated IRAK1 to interact with and thereby trans-
duce the signal to TRAF6. This signal causes the release of
Act1 from TRAF6. The IRAK1^TRAF6 complex then trans-
duces the signal to the TAB1/TAK1^NIK pathway, resulting
in activation of the IKK complex. Concurrently, the released
Act1 directly binds to IKKs to activate the IKK complex.
Therefore, activation of the IKK complex in both the
IRAK1^TRAF6 complex and Act1 pathways results in NF-
UB activation, and this duality may be useful for the e¡ective
signal transduction.
The TRAF domain serves as an adapter module and is
involved in interactions with various signal molecules. In ad-
dition to several molecules that are essential for TNF signal-
ing pathways [24], many other molecules, including TRIP
(TRAF-interacting protein), T2BP (TRAF2 binding protein),
and A20, interact with the TRAF domain of TRAF2
[19,25,26]. In case of TRAF6, TTRAP (TRAF and TNF-R
associated protein) and ECSIT (evolutionarily conserved sig-
naling intermediate in Toll pathways) have also been reported
to interact with the TRAF domain [27,28]. Although these
TRAF-domain-binding proteins a¡ect NF-UB and AP-1 acti-
vation of the TNF and IL-1/Toll signaling pathways, their
precise mechanisms are unclear. Our working model for
Act1 signaling pathways suggests that these TRAF-domain-
binding proteins may act similarly to Act1 in that the TRAF
proteins exchange their binding partners during ligand-in-
duced activation. Further analysis is necessary to evaluate
our working model.
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